Reference: 1. Ripin D, Prabhu VR. A cost-savings analysis of a candidate universal antiretroviral regimen. Curr Opin HIV AIDS. :@0.090607:0.822906:0.547382:0.822906:0.547382:0.814791:0.090607:0.814791:0.004821:0.004124:0.002406:0.004124:0.002750:0.004124:0.004301:0.003957:0.004124:0.001886:0.003827:0.004459:0.001886:0.003827:0.004821:0.001895:0.004301:0.001895:0.004301:0.003827:0.005165:0.001886:0.003827:0.004468:0.002750:0.004124:0.004301:0.004301:0.004301:0.003483:0.004292:0.004821:0.001886:0.003483:0.004645:0.003827:0.003957:0.004124:0.003781:0.002406:0.003270:0.003781:0.004217:0.003771:0.001895:0.004301:0.004301:0.003781:0.003827:0.004124:0.004301:0.004124:0.001895:0.003771:0.003781:0.001895:0.003781:0.003827:0.004124:0.002406:0.003827:0.004124:0.003827:0.003957:0.004124:0.004301:0.004301:0.001895:0.004301:0.004217:0.002406:0.004124:0.003827:0.004301:0.004301:0.001895:0.003771:0.004124:0.002750:0.003781:0.004124:0.001895:0.003827:0.004124:0.004301:0.002406:0.001895:0.002750:0.004124:0.002406:0.002750:0.004124:0.003771:0.001895:0.002750:0.004124:0.001895:0.003827:0.002750:0.004124:0.004301:0.001895:0.006707:0.004124:0.004301:0.001886:0.003827:0.004821:0.004301:0.002750:0.002750:0.003827:0.005165:0.004301:0.001895:0.004301:0.003827:0.004988:0.001895:0.004292:0.003483:0.004645:0.001895:0.005165:0.004645:0.001886:0.002229
2017;12:403–407 2. Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and :@0.090607:0.830418:0.547401:0.830418:0.547401:0.822303:0.090607:0.822303:0.004459:0.004459:0.004459:0.004459:0.002229:0.004459:0.004459:0.002229:0.004459:0.004459:0.004459:0.004645:0.004459:0.004459:0.004459:0.002090:0.004459:0.001886:0.002090:0.004988:0.001895:0.001895:0.001895:0.001746:0.004645:0.006539:0.001886:0.002090:0.006539:0.001895:0.002406:0.003957:0.004301:0.004124:0.001895:0.001895:0.002090:0.005165:0.001886:0.002090:0.004988:0.004301:0.004301:0.004301:0.004124:0.003781:0.002090:0.004645:0.001886:0.002090:0.004301:0.004124:0.003613:0.004301:0.001895:0.004124:0.004124:0.001746:0.004645:0.004124:0.001886:0.002090:0.004821:0.001895:0.003781:0.004124:0.003781:0.002090:0.004124:0.002406:0.002090:0.003957:0.004124:0.002750:0.004301:0.001895:0.004124:0.003771:0.004124:0.003781:0.003957:0.004301:0.001895:0.004124:0.002750:0.002090:0.004124:0.002750:0.002090:0.003957:0.004124:0.004301:0.002406:0.002750:0.004124:0.001895:0.002090:0.004301:0.004124:0.002917:0.003771:0.004124:0.004301:0.003781:0.002090:0.003781:0.003771:0.003781:0.002406:0.004124:0.006707:0.002090:0.004124:0.004301:0.003771:0.004124:0.002750:0.003781:0.004124:0.002090:0.004124:0.003771:0.004124:0.004301:0.002406:0.003781:0.002090:0.004124:0.004301:0.004301:0.002229
immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Curr :@0.090607:0.837930:0.547391:0.837930:0.547391:0.829815:0.090607:0.829815:0.001895:0.006707:0.006707:0.004301:0.004301:0.004124:0.002369:0.002750:0.004124:0.003957:0.004124:0.004301:0.003781:0.002406:0.001895:0.002406:0.004301:0.002406:0.001895:0.004124:0.004301:0.002369:0.001895:0.004301:0.002150:0.002150:0.004124:0.006707:0.006707:0.004217:0.002406:0.004124:0.002917:0.003771:0.002369:0.003781:0.003771:0.004301:0.004301:0.002750:0.004124:0.006707:0.004124:0.001886:0.002369:0.002406:0.004124:0.002750:0.002369:0.004301:0.004124:0.001895:0.004301:0.002406:0.004124:0.004301:0.002750:0.004217:0.003771:0.001895:0.002750:0.002369:0.003771:0.004124:0.002750:0.003781:0.004301:0.003781:0.002369:0.004124:0.002406:0.004301:0.004124:0.002750:0.002369:0.004124:0.004301:0.002406:0.001895:0.002750:0.004124:0.002406:0.002750:0.004124:0.003771:0.001895:0.002750:0.004124:0.001895:0.003781:0.001886:0.002369:0.006707:0.004124:0.002406:0.004124:0.003270:0.004124:0.004301:0.004124:0.001895:0.003771:0.003781:0.001895:0.003781:0.002369:0.004124:0.002406:0.002369:0.002750:0.004124:0.004301:0.004301:0.004124:0.006707:0.001895:0.003613:0.004124:0.004301:0.002369:0.002406:0.002750:0.001895:0.004124:0.001895:0.003781:0.001886:0.002369:0.004821:0.004301:0.002750:0.002750:0.002229
Opin HIV AIDS. 2018;13:102–111  3. McCoy C, Badowski M, Sherman E, et al. Strength in Amalgamation: Newer Combination Agents :@0.090607:0.845442:0.547429:0.845442:0.547429:0.837327:0.090607:0.837327:0.005165:0.004301:0.001895:0.004301:0.002248:0.004988:0.001895:0.004292:0.001904:0.004645:0.001895:0.005165:0.004645:0.001886:0.002248:0.004459:0.004459:0.004459:0.004459:0.002229:0.004459:0.004459:0.002229:0.004459:0.004459:0.004459:0.004645:0.004459:0.004459:0.004459:0.002248:0.002248:0.004459:0.001886:0.002248:0.006539:0.003957:0.004821:0.004217:0.003771:0.002248:0.004821:0.001886:0.002248:0.004821:0.004124:0.004301:0.004217:0.006019:0.003781:0.004124:0.001895:0.002248:0.006539:0.001886:0.002248:0.004645:0.004301:0.004124:0.002750:0.006707:0.004124:0.004301:0.002248:0.004301:0.001886:0.002248:0.004124:0.002406:0.002248:0.004124:0.001895:0.001886:0.002248:0.004645:0.002406:0.002750:0.004124:0.004301:0.004301:0.002406:0.004301:0.002248:0.001895:0.004301:0.001904:0.004645:0.006707:0.004124:0.001895:0.004301:0.004124:0.006707:0.004217:0.002406:0.001895:0.004124:0.004301:0.001886:0.002248:0.005165:0.004124:0.006019:0.004124:0.002750:0.002248:0.004821:0.004124:0.006707:0.004301:0.001895:0.004301:0.004217:0.002406:0.001895:0.004124:0.004301:0.001904:0.004645:0.004301:0.004124:0.004301:0.002406:0.003781:0.002229
for HIV and Implications for Practice. Pharmacotherapy. 2018;38(1):86–107  4. World Health Organization. HIV/AIDS. Dolutegravir (DTG) :@0.090607:0.852954:0.547447:0.852954:0.547447:0.844839:0.090607:0.844839:0.002406:0.004124:0.002750:0.001811:0.004988:0.001895:0.004292:0.001821:0.004124:0.004301:0.004301:0.001821:0.001895:0.006707:0.004301:0.001895:0.001895:0.003957:0.004217:0.002406:0.001895:0.004124:0.004301:0.003781:0.001811:0.002406:0.004124:0.002750:0.001821:0.004468:0.002750:0.004124:0.003957:0.002406:0.001895:0.003957:0.004124:0.001886:0.001821:0.004468:0.004301:0.004124:0.002750:0.006707:0.004124:0.003957:0.004124:0.002406:0.004301:0.004124:0.002750:0.004217:0.004301:0.003261:0.001886:0.001821:0.004459:0.004459:0.004459:0.004459:0.002229:0.004459:0.004459:0.002239:0.004459:0.002239:0.002229:0.004459:0.004459:0.004645:0.004459:0.004459:0.004459:0.001821:0.001821:0.004459:0.001886:0.001477:0.006539:0.004124:0.002750:0.001895:0.004301:0.001821:0.004988:0.004124:0.004124:0.001895:0.002406:0.004301:0.001811:0.005165:0.002750:0.004301:0.004124:0.004301:0.001895:0.003613:0.004217:0.002406:0.001895:0.004124:0.004301:0.001886:0.001821:0.004988:0.001895:0.004292:0.002582:0.004645:0.001895:0.005165:0.004645:0.001886:0.001811:0.005165:0.004124:0.001895:0.004301:0.002406:0.004124:0.004301:0.002750:0.004217:0.003771:0.001895:0.002750:0.001821:0.002239:0.005165:0.004301:0.004988:0.002239:0.002229
and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). Briefing note - 30 April 2018. [cited 2018 Sept 13] :@0.090607:0.860466:0.547354:0.860466:0.547354:0.852351:0.090607:0.852351:0.004124:0.004301:0.004301:0.002517:0.002406:0.004301:0.004124:0.002517:0.002150:0.002150:0.003771:0.004124:0.004301:0.002517:0.004301:0.004124:0.003781:0.004124:0.002517:0.003957:0.004124:0.006707:0.004301:0.001895:0.004301:0.004217:0.002406:0.001895:0.004124:0.004301:0.002517:0.002239:0.004124:0.005165:0.004821:0.002239:0.002517:0.004124:0.002406:0.002517:0.002406:0.004124:0.004301:0.004124:0.002406:0.004124:0.003771:0.001895:0.002750:0.002582:0.001895:0.004124:0.006707:0.001895:0.003771:0.004301:0.004301:0.001895:0.004301:0.004124:0.002582:0.004301:0.004124:0.001895:0.004301:0.002406:0.004124:0.004301:0.002750:0.004208:0.003771:0.001895:0.002750:0.002517:0.002239:0.004301:0.004124:0.005165:0.002239:0.001886:0.002517:0.004821:0.002750:0.001895:0.004124:0.002150:0.002150:0.004301:0.004301:0.002517:0.004301:0.004124:0.002406:0.004124:0.002517:0.003270:0.002517:0.004459:0.004459:0.002174:0.004737:0.004301:0.002750:0.001895:0.001895:0.002517:0.004459:0.004459:0.004459:0.004459:0.001886:0.002517:0.002406:0.003957:0.001895:0.002406:0.004124:0.004301:0.002517:0.004459:0.004459:0.004459:0.004459:0.002517:0.004645:0.004124:0.004301:0.002406:0.002517:0.004459:0.004459:0.002406:0.002229
Available from: http://www.who.int/hiv/pub/arv/dtg-tld-briefing/en/  5. World Health Organization. Policy Brief. HIV Treatment – Interim :@0.090607:0.867978:0.547438:0.867978:0.547438:0.859863:0.090607:0.859863:0.004645:0.003771:0.004124:0.001895:0.001895:0.004124:0.004301:0.001895:0.004124:0.001988:0.002406:0.002750:0.004124:0.006707:0.001886:0.001997:0.004301:0.002406:0.002406:0.004301:0.002229:0.002582:0.002582:0.006019:0.006019:0.005676:0.002229:0.006019:0.004301:0.004124:0.002229:0.001895:0.004301:0.002406:0.002582:0.004301:0.001895:0.003771:0.002582:0.004301:0.004301:0.004301:0.002582:0.004124:0.002917:0.003771:0.002582:0.004301:0.002406:0.004301:0.003270:0.002406:0.001895:0.004301:0.003270:0.004301:0.002750:0.001895:0.004124:0.002150:0.002150:0.004301:0.004301:0.002582:0.004124:0.004301:0.002582:0.001988:0.001997:0.004459:0.001886:0.001654:0.006539:0.004124:0.002750:0.001895:0.004301:0.001997:0.004988:0.004124:0.004124:0.001895:0.002406:0.004301:0.001988:0.005165:0.002750:0.004301:0.004124:0.004301:0.001895:0.003613:0.004217:0.002406:0.001895:0.004124:0.004301:0.001886:0.001997:0.004301:0.004124:0.001895:0.001895:0.003771:0.003771:0.001997:0.004821:0.002750:0.001895:0.004124:0.002406:0.001886:0.001997:0.004988:0.001895:0.004292:0.001654:0.003613:0.002750:0.004124:0.004217:0.002406:0.006707:0.004124:0.004301:0.002406:0.001997:0.004645:0.001997:0.001895:0.004301:0.002406:0.004124:0.002750:0.001895:0.006707:0.002229
Guidance. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and :@0.090607:0.875490:0.547429:0.875490:0.547429:0.867375:0.090607:0.867375:0.004988:0.004301:0.001895:0.004301:0.004124:0.004301:0.003957:0.004124:0.001886:0.003335:0.004821:0.004301:0.004301:0.004217:0.002406:0.004124:0.004301:0.003335:0.004821:0.004124:0.003957:0.004124:0.006707:0.006707:0.004124:0.004301:0.004301:0.004217:0.002406:0.001895:0.004124:0.004301:0.003781:0.003335:0.004124:0.004301:0.003335:0.003957:0.001895:0.002750:0.003781:0.002406:0.003270:0.004124:0.001895:0.004301:0.004124:0.003335:0.004124:0.004301:0.004301:0.003335:0.004645:0.004124:0.003957:0.004124:0.004301:0.004301:0.003270:0.004124:0.001895:0.004301:0.004124:0.002991:0.004645:0.004301:0.002406:0.001895:0.002750:0.004124:0.002406:0.002750:0.004124:0.003771:0.001895:0.002750:0.004124:0.001895:0.003335:0.004821:0.004124:0.004301:0.001895:0.006707:0.004124:0.004301:0.003781:0.003335:0.004124:0.004301:0.004301:0.003335:0.004301:0.004124:0.003781:0.002406:0.003270:0.004301:0.003771:0.004301:0.004124:0.003781:0.004301:0.002750:0.004124:0.003335:0.004468:0.002750:0.004124:0.004301:0.004301:0.003771:0.001895:0.004124:0.003771:0.001895:0.003781:0.003335:0.004124:0.004301:0.004301:0.002229
Recommendations on Early Infant Diagnosis of HIV. July 2018. [cited 2018 Sept 13]. Available from: http://www.who.int/hiv/pub/:@0.090607:0.883002:0.545199:0.883002:0.545199:0.874887:0.090607:0.874887:0.004821:0.004124:0.003957:0.004124:0.006707:0.006707:0.004124:0.004301:0.004301:0.004217:0.002406:0.001895:0.004124:0.004301:0.003781:0.003307:0.004124:0.004301:0.003307:0.004301:0.004124:0.002750:0.001895:0.003771:0.003307:0.001895:0.004301:0.002406:0.004124:0.004301:0.002406:0.003307:0.005165:0.001895:0.004217:0.004301:0.004301:0.004124:0.003781:0.001895:0.003781:0.003307:0.004124:0.002406:0.003307:0.004988:0.001895:0.003437:0.001886:0.003307:0.003957:0.004301:0.001895:0.003771:0.003307:0.004459:0.004459:0.004459:0.004459:0.001886:0.003307:0.002406:0.003957:0.001895:0.002406:0.004124:0.004301:0.003307:0.004459:0.004459:0.004459:0.004459:0.003307:0.004645:0.004124:0.004301:0.002406:0.003307:0.004459:0.004459:0.002406:0.001886:0.002963:0.004645:0.003771:0.004124:0.001895:0.001895:0.004124:0.004301:0.001895:0.004124:0.003307:0.002406:0.002750:0.004124:0.006707:0.001886:0.003307:0.004301:0.002406:0.002406:0.004301:0.002229:0.002582:0.002582:0.006019:0.006019:0.005676:0.002229:0.006019:0.004301:0.004124:0.002229:0.001895:0.004301:0.002406:0.002582:0.004301:0.001895:0.003771:0.002582:0.004301:0.004301:0.004301:0.002582
guidelines/ARV2018update/en/  6. Vitoria M, Hill A, Ford N, et al. The transition to dolutegravir and other new antiretrovirals in low-:@0.090607:0.890515:0.545116:0.890515:0.545116:0.882399:0.090607:0.882399:0.004301:0.004301:0.001895:0.004301:0.004124:0.001895:0.001895:0.004301:0.004124:0.003781:0.002582:0.004645:0.004821:0.004292:0.004459:0.004459:0.004459:0.004459:0.004301:0.004301:0.004301:0.004208:0.002406:0.004124:0.002582:0.004124:0.004301:0.002582:0.002675:0.002675:0.004459:0.001886:0.002332:0.004292:0.001895:0.002406:0.004124:0.002750:0.001895:0.004124:0.002675:0.006539:0.001886:0.002675:0.004988:0.001895:0.001895:0.001895:0.002341:0.004645:0.001886:0.002675:0.003939:0.004124:0.002750:0.004301:0.002675:0.005165:0.001886:0.002675:0.004124:0.002406:0.002675:0.004124:0.001895:0.001886:0.002332:0.004301:0.004301:0.004124:0.002675:0.002406:0.002750:0.004124:0.004301:0.003781:0.001895:0.002406:0.001895:0.004124:0.004301:0.002675:0.002406:0.004124:0.002675:0.004301:0.004124:0.001895:0.004301:0.002406:0.004124:0.004301:0.002750:0.004217:0.003771:0.001895:0.002750:0.002675:0.004124:0.004301:0.004301:0.002675:0.004124:0.002406:0.004301:0.004124:0.002750:0.002675:0.004301:0.004124:0.006019:0.002675:0.004124:0.004301:0.002406:0.001895:0.002750:0.004124:0.002406:0.002750:0.004124:0.003771:0.001895:0.002750:0.004124:0.001895:0.003781:0.002675:0.001895:0.004301:0.002675:0.001895:0.004217:0.006019:0.003270
income and middle-income countries: what are the issues? AIDS 2018;32:1551–1561 :@0.090607:0.898026:0.387953:0.898026:0.387953:0.889912:0.090607:0.889912:0.001895:0.004301:0.003957:0.004124:0.006707:0.004124:0.002229:0.004124:0.004301:0.004301:0.002229:0.006707:0.001895:0.004301:0.004301:0.001895:0.004124:0.003270:0.001895:0.004301:0.003957:0.004124:0.006707:0.004124:0.002229:0.003957:0.004124:0.004301:0.004301:0.002406:0.002750:0.001895:0.004124:0.003781:0.001886:0.002229:0.006019:0.004301:0.004217:0.002406:0.002229:0.004124:0.002750:0.004124:0.002229:0.002406:0.004301:0.004124:0.002229:0.001895:0.003781:0.003781:0.004301:0.004124:0.003781:0.004124:0.001886:0.004645:0.001895:0.005165:0.004645:0.002229:0.004459:0.004459:0.004459:0.004459:0.002229:0.004459:0.004459:0.002229:0.004459:0.004459:0.004459:0.004459:0.004645:0.004459:0.004459:0.004459:0.004459:0.002229
S4:@0.092001:0.913951:0.099105:0.913951:0.099105:0.905896:0.092001:0.905896:0.003823:0.003280
 EMDOLTEN. Reg. No.: 53/20.2.8/0082. Each film-coated tablet contains tenofovir disoproxil fumarate 300 mg, lamivudine 300 :@0.100357:0.913597:0.547443:0.913597:0.547443:0.905482:0.100357:0.905482:0.003019:0.004301:0.006539:0.005165:0.005165:0.003251:0.004301:0.004301:0.005165:0.001886:0.003019:0.004821:0.004124:0.004301:0.001886:0.003019:0.005165:0.004124:0.002229:0.001886:0.003019:0.004459:0.004459:0.002582:0.004459:0.004459:0.002229:0.004459:0.002229:0.004459:0.002582:0.004459:0.004459:0.004459:0.004459:0.001886:0.003019:0.004301:0.004124:0.003957:0.004301:0.003019:0.002150:0.002150:0.001895:0.006707:0.003270:0.003957:0.004124:0.004217:0.002406:0.004124:0.004301:0.003019:0.002406:0.004124:0.004301:0.001895:0.004124:0.002406:0.003019:0.003957:0.004124:0.004301:0.002406:0.004124:0.001895:0.004301:0.003781:0.003019:0.002406:0.004124:0.004301:0.004124:0.002406:0.004124:0.003771:0.001895:0.002750:0.003019:0.004301:0.001895:0.003781:0.004124:0.004301:0.002750:0.004124:0.003771:0.001895:0.001895:0.003019:0.002406:0.004301:0.006707:0.004124:0.002750:0.004217:0.002406:0.004124:0.003019:0.004459:0.004459:0.004459:0.003019:0.006707:0.004301:0.001886:0.003019:0.001895:0.004124:0.006707:0.001895:0.003771:0.004301:0.004301:0.001895:0.004301:0.004124:0.003019:0.004459:0.004459:0.004459:0.002229
mg and dolutegravir sodium equivalent to dolutegravir 50 mg. For full prescribing information refer to the professional information :@0.090604:0.921684:0.547397:0.921684:0.547397:0.913569:0.090604:0.913569:0.006707:0.004301:0.002787:0.004124:0.004301:0.004301:0.002796:0.004301:0.004124:0.001895:0.004301:0.002406:0.004124:0.004301:0.002750:0.004217:0.003771:0.001895:0.002750:0.002796:0.003781:0.004124:0.004301:0.001895:0.004301:0.006707:0.002787:0.004124:0.004301:0.004301:0.001895:0.003771:0.004124:0.001895:0.004124:0.004301:0.002406:0.002787:0.002406:0.004124:0.002787:0.004301:0.004124:0.001895:0.004301:0.002406:0.004124:0.004301:0.002750:0.004217:0.003771:0.001895:0.002750:0.002787:0.004459:0.004459:0.002787:0.006707:0.004301:0.001886:0.002796:0.003939:0.004124:0.002750:0.002787:0.002406:0.004301:0.001895:0.001895:0.002796:0.004301:0.002750:0.004124:0.003781:0.003957:0.002750:0.001895:0.004301:0.001895:0.004301:0.004301:0.002787:0.001895:0.004301:0.002406:0.004124:0.002750:0.006707:0.004217:0.002406:0.001895:0.004124:0.004301:0.002796:0.002750:0.004124:0.002406:0.004124:0.002750:0.002787:0.002406:0.004124:0.002796:0.002406:0.004301:0.004124:0.002787:0.004301:0.002750:0.004124:0.002406:0.004124:0.003781:0.003781:0.001895:0.004124:0.004301:0.004124:0.001895:0.002787:0.001895:0.004301:0.002406:0.004124:0.002750:0.006707:0.004217:0.002406:0.001895:0.004124:0.004301:0.002229
approved by the medicines regulatory authority (10/2018). Trademarks are owned by or licensed to the Aspen Group of companies. © :@0.090604:0.929770:0.547434:0.929770:0.547434:0.921655:0.090604:0.921655:0.004217:0.004301:0.004301:0.002750:0.004124:0.003771:0.004124:0.004301:0.002053:0.004301:0.003771:0.002053:0.002406:0.004301:0.004124:0.002053:0.006707:0.004124:0.004301:0.001895:0.003957:0.001895:0.004301:0.004124:0.003781:0.002053:0.002750:0.004124:0.004301:0.004301:0.001895:0.004217:0.002406:0.004124:0.002917:0.003771:0.002053:0.004124:0.004301:0.002406:0.004301:0.004124:0.002750:0.001895:0.002406:0.003771:0.002053:0.002239:0.004459:0.004459:0.002582:0.004459:0.004459:0.004459:0.004459:0.002239:0.001886:0.001709:0.003613:0.002750:0.004124:0.004301:0.004124:0.006707:0.004124:0.002750:0.004124:0.003781:0.002053:0.004124:0.002750:0.004124:0.002053:0.004217:0.006019:0.004301:0.004124:0.004301:0.002053:0.004301:0.003771:0.002053:0.004124:0.002750:0.002053:0.001895:0.001895:0.003957:0.004124:0.004301:0.003781:0.004124:0.004301:0.002053:0.002406:0.004124:0.002053:0.002406:0.004301:0.004124:0.001709:0.004645:0.003781:0.004301:0.004124:0.004301:0.002053:0.004988:0.002750:0.004124:0.004301:0.004301:0.002053:0.004124:0.002406:0.002053:0.003957:0.004124:0.006707:0.004301:0.004124:0.004301:0.001895:0.004124:0.003781:0.001886:0.002053:0.007431:0.002229
2018 Aspen Group of companies or its licensor. All rights reserved. Marketed by Aspen Pharmacare for Pharmacare Limited. Co. Reg. :@0.090604:0.937857:0.547416:0.937857:0.547416:0.929742:0.090604:0.929742:0.004459:0.004459:0.004459:0.004459:0.001895:0.004645:0.003781:0.004301:0.004124:0.004301:0.002239:0.004988:0.002750:0.004124:0.004301:0.004301:0.002239:0.004124:0.002406:0.002239:0.003957:0.004124:0.006707:0.004301:0.004124:0.004301:0.001895:0.004124:0.003781:0.002239:0.004124:0.002750:0.002239:0.001895:0.002406:0.003781:0.002239:0.001895:0.001895:0.003957:0.004124:0.004301:0.003781:0.004124:0.002062:0.001886:0.001895:0.004645:0.001895:0.001895:0.002239:0.002750:0.001895:0.004301:0.004301:0.002406:0.003781:0.002239:0.002750:0.004124:0.003781:0.004124:0.002917:0.003771:0.004124:0.004301:0.001886:0.002239:0.006539:0.004124:0.002750:0.004124:0.004124:0.002406:0.004124:0.004301:0.002239:0.004301:0.003771:0.001895:0.004645:0.003781:0.004301:0.004124:0.004301:0.002239:0.004468:0.004301:0.004124:0.002750:0.006707:0.004124:0.003957:0.004124:0.002750:0.004124:0.002239:0.002406:0.004124:0.002750:0.002239:0.004468:0.004301:0.004124:0.002750:0.006707:0.004124:0.003957:0.004124:0.002750:0.004124:0.002239:0.004124:0.001895:0.006707:0.001895:0.002406:0.004124:0.004301:0.001886:0.002239:0.004821:0.004124:0.001886:0.002239:0.004821:0.004124:0.004301:0.001886:0.002229
No.: 1898/000252/06. Healthcare Park, Woodlands Drive, Woodmead, 2191. :@0.090604:0.945944:0.352725:0.945944:0.352725:0.937829:0.090604:0.937829:0.005165:0.004124:0.002229:0.001886:0.002229:0.004459:0.004459:0.004459:0.004459:0.002582:0.004459:0.004459:0.004459:0.004459:0.004459:0.004459:0.002582:0.004459:0.004459:0.001886:0.002229:0.004988:0.004124:0.004124:0.001895:0.002406:0.004301:0.003957:0.004124:0.002750:0.004124:0.002229:0.004301:0.004124:0.002750:0.004124:0.001886:0.001886:0.006539:0.004124:0.004124:0.004301:0.001895:0.004124:0.004301:0.004301:0.003781:0.002229:0.005165:0.002750:0.001895:0.003771:0.004124:0.001886:0.001886:0.006539:0.004124:0.004124:0.004301:0.006707:0.004124:0.004124:0.004301:0.001886:0.002229:0.004459:0.004459:0.004459:0.004459:0.001886:0.002229
ZAR-BKS-1018-2226  12/18:@0.090604:0.953456:0.188836:0.953456:0.188836:0.945341:0.090604:0.945341:0.004301:0.004645:0.004821:0.003270:0.004821:0.004645:0.004645:0.003270:0.004459:0.004459:0.004459:0.004459:0.003270:0.004459:0.004459:0.004459:0.004459:0.002229:0.002229:0.004459:0.004459:0.002582:0.004459:0.004459
A step forward in the treatment of HIV :@0.090607:0.452143:0.700162:0.452143:0.700162:0.421821:0.090607:0.421821:0.022799:0.009253:0.017873:0.011716:0.019105:0.020336:0.009253:0.011083:0.020336:0.012947:0.027093:0.019105:0.012348:0.020336:0.009253:0.008587:0.019737:0.009253:0.011716:0.019737:0.019105:0.009253:0.011716:0.012348:0.019105:0.019105:0.011716:0.030155:0.019105:0.019737:0.011716:0.009253:0.020336:0.011083:0.009253:0.024663:0.009819:0.020969:0.009253
giving more people HOPE :@0.090607:0.483329:0.506585:0.483329:0.506585:0.453008:0.090607:0.453008:0.020336:0.008587:0.017307:0.008587:0.019737:0.020336:0.009253:0.030155:0.020336:0.012348:0.019105:0.009253:0.020336:0.019105:0.020336:0.020336:0.008587:0.019105:0.009253:0.024663:0.025895:0.022200:0.021568:0.009253
1-4:@0.506586:0.472562:0.536061:0.472562:0.536061:0.454885:0.506586:0.454885:0.010789:0.007898:0.010789
1:@0.181339:0.364635:0.196923:0.364635:0.196923:0.339764:0.181339:0.339764:0.015584
   INSTI +       NRTIs =       in 1 combination: TLD:@0.196923:0.364635:0.814696:0.364635:0.814696:0.339764:0.196923:0.339764:0.007792:0.007792:0.007792:0.007259:0.020236:0.018162:0.016088:0.007259:0.007792:0.016817:0.007792:0.007792:0.007792:0.015584:0.007792:0.007792:0.007792:0.020236:0.018695:0.016088:0.007259:0.014014:0.007792:0.016817:0.007792:0.007792:0.007792:0.015584:0.007792:0.007792:0.007792:0.006222:0.015584:0.007792:0.015584:0.007792:0.015051:0.016088:0.023908:0.016621:0.006222:0.015584:0.015051:0.008829:0.006222:0.016088:0.015584:0.007792:0.007792:0.016088:0.015584:0.019732
2:@0.337289:0.364635:0.352873:0.364635:0.352873:0.339764:0.337289:0.339764:0.015584
3:@0.500526:0.364635:0.516110:0.364635:0.516110:0.339764:0.500526:0.339764:0.015584
ONCE DAILY:@0.413134:0.399587:0.582873:0.399587:0.582873:0.374052:0.413134:0.374052:0.021806:0.020769:0.020769:0.018162:0.007792:0.020769:0.019199:0.008268:0.013510:0.018695
A DTG based regimen may be recommended as a preferred  :@0.090607:0.545865:0.744856:0.545865:0.744856:0.525190:0.090607:0.525190:0.015545:0.006309:0.016816:0.013866:0.017224:0.006309:0.013866:0.013026:0.012186:0.013026:0.013866:0.006309:0.008419:0.013026:0.013866:0.005855:0.020560:0.013026:0.013457:0.006309:0.020560:0.013026:0.011778:0.006309:0.013866:0.013026:0.006309:0.008419:0.013026:0.013026:0.013866:0.020560:0.020560:0.013026:0.013457:0.013866:0.013026:0.013866:0.006309:0.013026:0.012186:0.006309:0.013026:0.006309:0.013866:0.008419:0.013026:0.007557:0.013026:0.008828:0.008419:0.013026:0.013866:0.006309:0.006309
first-line regimen for people living with HIV initiating ART.  :@0.090607:0.568965:0.730682:0.568970:0.730682:0.548296:0.090607:0.548291:0.006933:0.006933:0.008828:0.012186:0.007988:0.009236:0.005855:0.005855:0.013457:0.013026:0.006309:0.008419:0.013026:0.013866:0.005855:0.020560:0.013026:0.013457:0.006309:0.007557:0.013866:0.008828:0.006309:0.013866:0.013026:0.013866:0.013866:0.005855:0.013026:0.006309:0.005855:0.005855:0.011801:0.005855:0.013457:0.013866:0.006309:0.018472:0.005855:0.007988:0.013457:0.006309:0.016816:0.006695:0.014297:0.006309:0.005855:0.013457:0.005855:0.007988:0.005855:0.013026:0.007988:0.005855:0.013457:0.013866:0.006309:0.015545:0.015976:0.011347:0.006309:0.018391:-0.132857
4,5:@0.705984:0.561624:0.724374:0.561624:0.724374:0.549571:0.705984:0.549571:0.007356:0.003678:0.007356
DTG-based regimens vs. EFV/NNRTI regimens:@0.090617:0.601377:0.576640:0.601377:0.576640:0.581049:0.090617:0.581049:0.016385:0.013457:0.017224:0.008828:0.013866:0.012618:0.011778:0.012618:0.013866:0.006309:0.007580:0.012618:0.013457:0.005469:0.019743:0.012618:0.013026:0.011778:0.006309:0.011778:0.011778:0.006309:0.006309:0.014297:0.013457:0.013866:0.007988:0.016385:0.016385:0.015568:0.013457:0.006309:0.006309:0.007580:0.012618:0.013457:0.005469:0.019743:0.012618:0.013026:0.011778
•:@0.090607:0.627509:0.101198:0.627509:0.101198:0.608715:0.090607:0.608715:0.010590
  Offer faster viral suppression:@0.101198:0.627509:0.390800:0.627509:0.390800:0.608715:0.101198:0.608715:0.005888:0.012264:0.016097:0.005888:0.006270:0.011374:0.007053:0.005888:0.006270:0.011374:0.010590:0.006672:0.011374:0.007053:0.005888:0.010590:0.004702:0.007053:0.011374:0.004702:0.005888:0.010590:0.011776:0.012560:0.012560:0.006672:0.011374:0.010590:0.010590:0.004702:0.012158:0.011776
1,4,5:@0.390803:0.620707:0.418265:0.620707:0.418265:0.609750:0.390803:0.609750:0.006866:0.003433:0.006866:0.003433:0.006866
  :@0.418265:0.627509:0.430042:0.627509:0.430042:0.608715:0.418265:0.608715:0.005888:0.005888
•:@0.090602:0.654084:0.101192:0.654084:0.101192:0.635289:0.090602:0.635289:0.010590
  Higher genetic barrier to resistance:@0.101192:0.654084:0.451180:0.654084:0.451180:0.635289:0.101192:0.635289:0.005888:0.012264:0.015292:0.004702:0.012158:0.011776:0.011374:0.007053:0.005888:0.012158:0.011374:0.011776:0.011374:0.006672:0.004702:0.011374:0.005888:0.012560:0.011374:0.007053:0.007053:0.004702:0.011374:0.007053:0.005888:0.006672:0.012158:0.005888:0.006672:0.011374:0.010590:0.004702:0.010590:0.006672:0.011374:0.011776:0.011374:0.011374
1,4,5,6 :@0.451183:0.647279:0.492376:0.647279:0.492376:0.636322:0.451183:0.636322:0.006866:0.003433:0.006866:0.003433:0.006866:0.003433:0.006866:0.003433
•:@0.090607:0.680653:0.101198:0.680653:0.101198:0.661858:0.090607:0.661858:0.010590
  Improve tolerability:@0.101198:0.680653:0.299406:0.680653:0.299406:0.661858:0.101198:0.661858:0.005888:0.012264:0.005486:0.018067:0.012560:0.006672:0.012158:0.010590:0.011374:0.005888:0.006672:0.012158:0.004702:0.011374:0.007053:0.011374:0.012560:0.004702:0.004702:0.004702:0.006672:0.010590
1,4,6:@0.299406:0.673851:0.326869:0.673851:0.326869:0.662893:0.299406:0.662893:0.006866:0.003433:0.006866:0.003433:0.006866
•:@0.090607:0.707225:0.101198:0.707225:0.101198:0.688430:0.090607:0.688430:0.010590
  Enhance treatment simplification and adherence:@0.101198:0.707225:0.575664:0.707225:0.575664:0.688430:0.101198:0.688430:0.005888:0.012264:0.012941:0.011776:0.011776:0.011374:0.011776:0.011374:0.011374:0.005888:0.006672:0.006672:0.011374:0.011374:0.006672:0.018067:0.011374:0.011776:0.006672:0.005888:0.010590:0.004702:0.018067:0.012560:0.004702:0.004702:0.005486:0.005486:0.011374:0.011374:0.006672:0.004702:0.012158:0.011776:0.005888:0.011374:0.011776:0.012560:0.005888:0.011374:0.012560:0.011776:0.011374:0.006672:0.011374:0.011776:0.011374:0.011374
1-5:@0.575662:0.700422:0.594197:0.700422:0.594197:0.689465:0.575662:0.689465:0.006866:0.004803:0.006866
ART= Antiretroviral therapy; EFV = Efavirenz; DTG = Dolutegravir; FDC = Fixed-dose combination; :@0.090607:0.743575:0.530205:0.743575:0.530205:0.733002:0.090607:0.733002:0.006052:0.006064:0.005604:0.007262:0.002457:0.006052:0.005604:0.003135:0.002469:0.003583:0.005374:0.003135:0.003583:0.005374:0.004914:0.002469:0.003583:0.005374:0.002469:0.002905:0.003135:0.005604:0.005374:0.003583:0.005495:0.005604:0.004914:0.002905:0.002905:0.005604:0.005374:0.005592:0.002905:0.007262:0.002905:0.005604:0.003135:0.005495:0.004914:0.002469:0.003583:0.005374:0.005604:0.004708:0.002905:0.002905:0.006729:0.005604:0.006499:0.002905:0.007262:0.002905:0.006729:0.005374:0.002469:0.005604:0.003135:0.005374:0.005604:0.003583:0.005495:0.004914:0.002469:0.003583:0.002905:0.002905:0.005374:0.006729:0.006281:0.002905:0.007262:0.002905:0.005156:0.002469:0.004914:0.005374:0.005604:0.004260:0.005604:0.005374:0.004926:0.005374:0.002905:0.005156:0.005374:0.008738:0.005604:0.002469:0.005604:0.005495:0.003135:0.002469:0.005374:0.005604:0.002905:0.002905
HIV = Human Immunodeficiency Virus; INSTI = Integrase Strand Transfer Inhibitor; :@0.090607:0.754666:0.458797:0.754666:0.458797:0.744093:0.090607:0.744093:0.006499:0.002469:0.005592:0.002905:0.007262:0.002905:0.006499:0.005604:0.008738:0.005374:0.005604:0.002905:0.002469:0.008738:0.008738:0.005604:0.005604:0.005374:0.005604:0.005374:0.002802:0.002802:0.005156:0.002469:0.005374:0.005604:0.004914:0.004914:0.002457:0.005592:0.002469:0.003583:0.005604:0.004926:0.002905:0.002905:0.002469:0.006729:0.006052:0.005604:0.002469:0.002905:0.007262:0.002905:0.002469:0.005604:0.003135:0.005374:0.005604:0.003583:0.005374:0.004926:0.005374:0.002905:0.006052:0.003135:0.003583:0.005374:0.005604:0.005604:0.002457:0.004708:0.003583:0.005374:0.005604:0.004926:0.003135:0.005374:0.003583:0.002905:0.002469:0.005604:0.005604:0.002469:0.005604:0.002469:0.003135:0.005374:0.003583:0.002905:0.002905
NRTI = nucleoside reverse transcriptase inhibitor; NNRTI= Non-nucleoside reverse transcriptase inhibitor; :@0.090607:0.765757:0.564094:0.765757:0.564094:0.755184:0.090607:0.755184:0.006729:0.006064:0.005604:0.002469:0.002905:0.007262:0.002905:0.005604:0.005604:0.004914:0.002469:0.005374:0.005374:0.004926:0.002469:0.005604:0.005374:0.002905:0.003583:0.005374:0.004914:0.005374:0.003583:0.004926:0.005374:0.002905:0.003135:0.003583:0.005374:0.005604:0.004926:0.005156:0.003583:0.002469:0.005604:0.003135:0.005374:0.004926:0.005374:0.002905:0.002469:0.005604:0.005604:0.002469:0.005604:0.002469:0.003135:0.005374:0.003583:0.002905:0.002905:0.006729:0.006729:0.006064:0.005604:0.002469:0.007262:0.002905:0.006729:0.005374:0.005604:0.004260:0.005604:0.005604:0.004914:0.002469:0.005374:0.005374:0.004926:0.002469:0.005604:0.005374:0.002905:0.003583:0.005374:0.004914:0.005374:0.003583:0.004926:0.005374:0.002905:0.003135:0.003583:0.005374:0.005604:0.004926:0.005156:0.003583:0.002469:0.005604:0.003135:0.005374:0.004926:0.005374:0.002905:0.002469:0.005604:0.005604:0.002469:0.005604:0.002469:0.003135:0.005374:0.003583:0.002905:0.002905
TLD = tenofovir disoproxil fumarate, lamivudine and dolutegravir:@0.090607:0.776848:0.378952:0.776848:0.378952:0.766274:0.090607:0.766274:0.005604:0.005374:0.006729:0.002905:0.007262:0.002905:0.003135:0.005374:0.005604:0.005374:0.003135:0.005374:0.004914:0.002469:0.003583:0.002905:0.005604:0.002469:0.004926:0.005374:0.005604:0.003583:0.005374:0.004914:0.002469:0.002469:0.002905:0.003135:0.005604:0.008738:0.005374:0.003583:0.005495:0.003135:0.005374:0.002457:0.002905:0.002469:0.005374:0.008738:0.002469:0.004914:0.005604:0.005604:0.002469:0.005604:0.005374:0.002905:0.005374:0.005604:0.005604:0.002905:0.005604:0.005374:0.002469:0.005604:0.003135:0.005374:0.005604:0.003583:0.005495:0.004914:0.002469:0.003583
300 mg Tenofovir Disoproxil Fumarate:@0.092630:0.249138:0.583729:0.249138:0.583729:0.218605:0.092630:0.218605:0.016777:0.016777:0.016777:0.008388:0.025235:0.016182:0.007095:0.013596:0.015518:0.016182:0.015518:0.009052:0.015518:0.014190:0.007130:0.010346:0.008388:0.019433:0.007130:0.014225:0.015518:0.016182:0.010346:0.015518:0.014190:0.007130:0.007130:0.008388:0.015518:0.016182:0.025235:0.015518:0.010346:0.015868:0.009052:0.015518
300 mg Lamivudine:@0.209507:0.280979:0.466818:0.280979:0.466818:0.250446:0.209507:0.250446:0.016777:0.016777:0.016777:0.008388:0.025235:0.016182:0.008388:0.015518:0.015518:0.025235:0.007130:0.014190:0.016182:0.016182:0.007130:0.016182:0.015518
50 mg Dolutegravir:@0.213841:0.312820:0.462484:0.312820:0.462484:0.282287:0.213841:0.282287:0.016777:0.016777:0.008388:0.025235:0.016182:0.008388:0.019433:0.015518:0.007130:0.016182:0.009052:0.015518:0.016182:0.010346:0.015868:0.014190:0.007130:0.010346
NEW:@0.751125:0.452495:0.846635:0.452495:0.846635:0.415199:0.751125:0.415199:0.030336:0.026528:0.038646
FIXED:@0.771488:0.467725:0.826271:0.467725:0.826271:0.450772:0.771488:0.450772:0.011035:0.005490:0.012412:0.012058:0.013789
DOSE:@0.772679:0.482887:0.825080:0.482887:0.825080:0.465934:0.772679:0.465934:0.013789:0.014477:0.012077:0.012058